R. Cosentini (Milan, Italy), M. Van Der Eerden (Rotterdam, Netherlands)
Validation of community-acquired pneumonia: high positive predictive value for ICD-9 codes
E. van de Garde, V. Deneer, P. Souverein, J. van den Bosch, H. Leufkens (Nieuwegein, Utrecht, Netherlands)
|  |
Divergence in diagnostic of pneumonia between out-patients‘ clinic and hospital data
R. Bontsevich (Labytnangi, Russian Federation)
|  |
Influence of antibiotic pre-treatment on pro-atrial natriuretic peptide in community-acquired pneumonia
S. Krueger, J. Kunde, A. Hanschmann, R. Marre, N. Suttorp, T. Welte (Aachen, Hennigsdorf, Ulm, Berlin, Hannover, Germany)
| |
CURB-65 severity assessment using continuous, weighted variables
B. Jones, J. Al, M. Marc-Aurel, G. Snow, S. Crapo, N. Dean (Murray, UT, Salt Lake City, UT, United States Of America)
| |
Thrombocytosis predicts poor outcomes in patients with community-acquired pneumonia: results from the CAPO international cohort study
M. Mirsaeidi, P. Peyrani, S. Aliberti, G. Filardo, F. Blasi, H. Lode, J. M. Luna, M. T. Parada, J. Ramirez, The CAPO Investigators (Louisville, KY, Dallas, TX, United States Of America; Milan, Italy; Berlin, Germany; Guatemala, Guatemala; Santiago, Chile
| |
D-dimer is an independent marker predicting severity in community acquired pneumonia
J. Chalmers, A. Singanayagam, C. Scally, A. Hill (Edinburgh, Perth, United Kingdom)
| |
Prognostic score systems and bacteraemic pneumococcal pneumonia (BPP)
M. Garcia-Clemente, J. M. Garcia-Garcia, F. Alvarez-Navascues, M. Martinez-Muniz, A. Sanchez-Antuña, J. Allende-Gonzalez, G. Sierra-Dorado (Aviles. Asturias, Spain)
| |
Total antioxidant capacity and C-reactive protein levels in patients with community acquired pneumonia
A. Bircan, R. Sutcu, M. Gokirmak, H. Hicyilmaz, A. Akkaya, O. Ozturk (Isparta, Turkey)
| |
Sputum and streptococcus pneumoniae urinary antigen test for diagnosis of pneumococcal community acquired pneumonia
S. Krueger, C. Schumann, R. Marre, N. Suttorp, T. Welte (Aachen, Ulm, Berlin, Hannover, Germany)
| |
The incidence of Q fever in hospitalized patients with community acquired pneumonia
I. Kondova Topuzovska, G. Kondov, A. Anastasovska, S. Petrusevska Marinkovic, V. Semenakova Cvetkovska (Skopje, Fyrom)
| |
Quality and quantity detection of Legionella in environment water samples
Y. Alyapkina, I. Tartakovsky, T. Karpova, D. Varlamov, Y. Pashko, Y. Dronina (Moscow, Russian Federation)
| |
Impact of determination of urine pneumococcal antigen in the diagnosis of community acquired pneumonia
A. Reina, I. Alfageme, J. Gallego, N. Reyes, M. J. Garcia (Seville, Spain)
| |
Etiologic evaluation of community acquired pneumonia
C. Naz, F. Alatas, G. Durmaz, H. Yildirim, G. Ak, A. Kiremitci, S. Erginel, M. Metintas (Eskisehir, Turkey)
| |
Sputum gram-stain phagocyte examination: sensitivity and specificity for identifying causative organisms of pneumonia
H. Ono, N. Nishimura, N. Chohnabayashi, O. Takahashi, K. Furukawa (Tokyo, Japan)
| |
Aetiology of community-acquired pneumonia and length of stay
D. Snijders, C. de Graaff, W. Boersma (Alkmaar, Netherlands)
| |
Practical treatment of community acquired pneumonia (CAP) with outpatient parenteral antibiotic therapy (OPAT) and switch therapy: CTRX and LVFX
M. Kato, U. Sohta, C. Yonemoto, Y. Koshimo, N. Tanabe, K. Miura, S. Goto, M. Kawashima (Kishiwada/Osaka, Japan)
| |
Predicting severe sepsis in community-acquired pneumonia using CURB65 and PSI scores
R. Cosentini, A. M. Brambilla, F. Piffer, S. Aliberti, F. Tantardini, T. Maraffi, F. Tardini, A. Torri (Milan, Italy)
| |
Inflammatory parameters and CRB-65 score in community acquired pneumonia caused by atypical pathogens
S. Krueger, J. Kunde, A. Hanschmann, R. Marre, N. Suttorp, T. Welte (Aachen, Hennigsdorf, Ulm, Berlin, Hannover, Germany)
| |
Pneumonia on ultrasound: a madness?
L. G. Vittorino, B. Antonio (Cosenza, Italy)
| |
Exhaled nitric oxide (NO) detection for monitoring airway inflammation in non-severe CAP
C. Jungnitz, K. Dalhoff, B. Schaaf, P. Zabel, D. Droemann (Lübeck, Borstel, Germany)
| |